Shell Asset Management CO Bristol Myers Squibb CO Transaction History

Shell Asset Management CO

$2.2 Billion
Q1 2024

A detailed history of Shell Asset Management CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Shell Asset Management CO holds 70,314 shares of BMY stock, worth $3.74 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

70,314

Previous 78,213 10.1%

Holding current value

$3.74 Million

Previous $4.24 Million 31.15%

% of portfolio

0.13%

Previous 0.19%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 31, 2024	SELL	$47.98 - $54.4 $378,994 - $429,705	-7,899 Reduced 10.1%	70,314 $2.92 Million
Q1 2024 May 14, 2024	BUY	$47.98 - $54.4 $205,690 - $233,212	4,287 Added 5.8%	78,213 $4.24 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $1.1 Million - $1.31 Million	-22,630 Reduced 23.44%	73,926 $3.79 Million
Q3 2023 Nov 08, 2023	SELL	$57.89 - $64.73 $93,955 - $105,056	-1,623 Reduced 1.65%	96,556 $5.6 Million
Q2 2023 Jul 28, 2023	SELL	$63.71 - $70.74 $2.5 Million - $2.78 Million	-39,230 Reduced 28.55%	98,179 $6.28 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $521,408 - $591,395	-7,935 Reduced 5.46%	137,409 $9.52 Million
Q4 2022 Feb 07, 2023	BUY	$68.48 - $81.09 $336,236 - $398,151	4,910 Added 3.5%	145,344 $10.5 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $4,663 - $2.76 Million	-35,872 Reduced 20.35%	140,434 $9.98 Million
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $465,494 - $512,671	-6,410 Reduced 3.51%	176,306 $13.6 Million
Q1 2022 May 04, 2022	SELL	$61.48 - $73.72 $2.43 Million - $2.91 Million	-39,479 Reduced 17.77%	182,716 $13.3 Million
Q4 2021 Feb 09, 2022	BUY	$53.63 - $62.52 $795,922 - $927,859	14,841 Added 7.16%	222,195 $13.9 Million
Q3 2021 Nov 04, 2021	SELL	$59.17 - $69.31 $3.06 Million - $3.59 Million	-51,785 Reduced 19.98%	207,354 $12.3 Million
Q2 2021 Aug 12, 2021	SELL	$61.91 - $67.42 $1.51 Million - $1.65 Million	-24,435 Reduced 8.62%	259,139 $17.3 Million
Q1 2021 May 10, 2021	BUY	$59.34 - $66.74 $5.66 Million - $6.36 Million	95,322 Added 50.64%	283,574 $17.9 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $925,860 - $1.05 Million	-16,035 Reduced 7.85%	188,252 $11.7 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $1.86 Million - $2.06 Million	32,331 Added 18.8%	204,287 $12.3 Million
Q2 2020 Aug 10, 2020	SELL	$54.82 - $64.09 $1.1 Million - $1.29 Million	-20,146 Reduced 10.49%	171,956 $10.1 Million
Q1 2020 May 11, 2020	BUY	$46.4 - $67.43 $453,328 - $658,791	9,770 Added 5.36%	192,102 $10.7 Million
Q4 2019 Feb 13, 2020	BUY	$49.21 - $64.19 $1.78 Million - $2.32 Million	36,078 Added 24.67%	182,332 $11.7 Million
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $637,315 - $755,629	14,901 Added 11.34%	146,254 $7.42 Million
Q2 2019 Aug 12, 2019	BUY	$44.62 - $49.34 $50,286 - $55,606	1,127 Added 0.87%	131,353 $5.96 Million
Q4 2018 Feb 13, 2019	SELL	$48.76 - $63.23 $1.04 Million - $1.35 Million	-21,329 Reduced 14.07%	130,226 $6.77 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $522,152 - $588,947	-9,461 Reduced 5.88%	151,555 $9.41 Million
Q2 2018 Aug 10, 2018	SELL	$50.53 - $62.98 $2.45 Million - $3.05 Million	-48,417 Reduced 23.12%	161,016 $8.91 Million
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $370,485 - $426,503	6,183 Added 3.04%	209,433 $13.2 Million
Q4 2017 Feb 09, 2018	BUY	$59.94 - $65.35 $1.59 Million - $1.73 Million	26,458 Added 14.97%	203,250 $12.5 Million
Q3 2017 Oct 20, 2017	SELL	$55.23 - $63.74 $17 Million - $19.6 Million	-307,433 Reduced 63.49%	176,792 $11.3 Million
Q3 2017 Oct 18, 2017	BUY	$55.23 - $63.74 $26.7 Million - $30.9 Million	484,225	484,225 $24.8 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Bristol Myers Squibb CO Transaction History